These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859 [TBL] [Abstract][Full Text] [Related]
4. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019 [TBL] [Abstract][Full Text] [Related]
5. Role of Long-Acting Muscarinic Antagonist/Long-Acting β Petite SE Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560 [TBL] [Abstract][Full Text] [Related]
6. Stepwise management of COPD: What is next after bronchodilation? Miravitlles M; Matsunaga K; Dreher M Ther Adv Respir Dis; 2023; 17():17534666231208630. PubMed ID: 37936381 [TBL] [Abstract][Full Text] [Related]
7. Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. Nici L; Mammen MJ; Charbek E; Alexander PE; Au DH; Boyd CM; Criner GJ; Donaldson GC; Dreher M; Fan VS; Gershon AS; Han MK; Krishnan JA; Martinez FJ; Meek PM; Morgan M; Polkey MI; Puhan MA; Sadatsafavi M; Sin DD; Washko GR; Wedzicha JA; Aaron SD Am J Respir Crit Care Med; 2020 May; 201(9):e56-e69. PubMed ID: 32283960 [No Abstract] [Full Text] [Related]
8. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids. Asche CV; Leader S; Plauschinat C; Raparla S; Yan M; Ye X; Young D Int J Chron Obstruct Pulmon Dis; 2012; 7():201-9. PubMed ID: 22500120 [TBL] [Abstract][Full Text] [Related]
9. A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease. D'Urzo A; Donohue JF; Kardos P; Miravitlles M; Price D Expert Opin Pharmacother; 2015; 16(12):1845-60. PubMed ID: 26194213 [TBL] [Abstract][Full Text] [Related]
10. Dual LABA/LAMA Therapy versus LABA or LAMA Monotherapy for Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis in Support of the American Thoracic Society Clinical Practice Guideline. Mammen MJ; Pai V; Aaron SD; Nici L; Alhazzani W; Alexander PE Ann Am Thorac Soc; 2020 Sep; 17(9):1133-1143. PubMed ID: 32530702 [No Abstract] [Full Text] [Related]
11. Effectiveness of Treatment With Dual Bronchodilation (LABA/LAMA) Compared With Combination Therapy (LABA/ICS) for Patients With COPD: A Population-Based Study. Monteagudo M; Nuñez A; Barrecheguren M; Miravitlles M Arch Bronconeumol; 2022 Oct; 58(10):699-707. PubMed ID: 35618580 [TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Long-Acting Beta Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405 [TBL] [Abstract][Full Text] [Related]
14. Can Assessment of Disease Burden Prior to Changes in Initial COPD Maintenance Treatment Provide Insight into Remaining Unmet Needs? A Retrospective Database Study in UK Primary Care. Landis SH; Wurst K; Le HV; Bonar K; Punekar YS COPD; 2017 Feb; 14(1):80-85. PubMed ID: 27819513 [TBL] [Abstract][Full Text] [Related]
15. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study. Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047 [TBL] [Abstract][Full Text] [Related]
16. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes. Hizawa N Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659 [TBL] [Abstract][Full Text] [Related]
17. DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach. Singh D; Litewka D; Páramo R; Rendon A; Sayiner A; Tanni SE; Acharya S; Aggarwal B; Ismaila AS; Sharma R; Daley-Yates P Adv Ther; 2023 Oct; 40(10):4282-4297. PubMed ID: 37382864 [TBL] [Abstract][Full Text] [Related]
18. Triple Inhaler versus Dual Bronchodilator Therapy in COPD: Real-World Effectiveness on Mortality. Suissa S; Dell'Aniello S; Ernst P COPD; 2022 Dec; 19(1):1-9. PubMed ID: 34544314 [TBL] [Abstract][Full Text] [Related]
19. Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA Ann Pharmacother; 2017 Nov; 51(11):945-953. PubMed ID: 28677404 [TBL] [Abstract][Full Text] [Related]
20. Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study. Wurst KE; Shukla A; Muellerova H; Davis KJ COPD; 2014 Sep; 11(5):521-30. PubMed ID: 24945236 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]